Table 1 Patient and clinical characteristics

From: Predicting breast cancer response to neoadjuvant chemotherapy using pretreatment diffuse optical spectroscopic texture analysis

Patient and tumour characteristics

n =37 (All subjects)

Patients

Age (years)

50

Pretreatment tumour size (MRI, cm)

Responders

5.4

Non-responders

7.0

Molecular and histological features

ER+

27

Triple negative/basal-like

7

HER2+

12

Invasive ductal carcinoma

36

Invasive lobular carcinoma

1

Treatment response classification

Responders

27

Non-responders

10

Chemotherapy and targeted therapies

AC-T

21

FEC-D

16

Trastuzumab

12

  1. Abbreviations: AC-T=adriamycin, cyclophosphamide, taxol; ER, oestrogen receptor; FEC-D=fluorouracil, epirubicin, cyclophosphamide, docetaxel; MRI, magnetic resonance imaging.
  2. Patients included in the study were diagnosed with biopsy-confirmed locally advanced breast cancer, and received a combination of anthracycline and taxane-based chemotherapies following standard institutional guidelines.
Back to article page